Fosrenol (lanthanum carbonate) / Takeda - LARVOL DELTA

Phytase-mimetic sulfated lanthanum oxycarbonate nanorods: A potential alternative for degrading phytic acid and enhancing nutrient bioavailability in cereal-based feeds. (PubMed, Int J Biol Macromol) - "Furthermore, in vitro digestion confirmed the efficacy of SLOC-NRs in degrading phytic acid under controlled conditions. These results suggest that SLOC-NRs could serve as a viable alternative to native enzymes, significantly enhancing the nutritional quality of cereal-based feeds and improving mineral bioavailability in monogastric diets."

Journal

Phosphate binders suppress glutaminase activity for treatment of cirrhosis and hepatic encephalopathy murine models. (PubMed, Biochem Pharmacol) - "The pharmacology and pharmacodynamics of Pi binders (sevelamer and lanthanum carbonate) were evaluated in CCl4-induced cirrhosis and both type A and C HE murine models...They had better therapeutic effects than L-ornithine L-aspartate (OA). Pi deprivation weakened glutaminase enzymatic activity, lowering collagen and Alpha-smooth muscle actin (α-SMA) production in HSCs and ammonia production in both wild-type and GLS1-overexpressing IECs. Since Pi deprivation alleviates glutaminolysis and ammonia production by decreasing glutaminase activity, Pi binders might hold great promising to treat cirrhosis and HE."

Journal • Preclinical • CNS Disorders • Fibrosis • Hepatic Encephalopathy • Hepatology • Immunology • Liver Failure • GLS1

Short-term lanthanum carbonate reduces calcification of cryopreserved aortic allografts in the young: A Porcine circulatory transplant model. (PubMed, Gen Thorac Cardiovasc Surg) - "Our results suggest that short-term lanthanum carbonate administration may alleviate cryopreserved allograft calcification in young recipients, without adverse effects."

Journal • Preclinical • Inflammation • Metabolic Disorders • Nephrology • Pediatrics • Transplantation

Association Between Serum 25-Hydroxyvitamin D and Bone Metabolism in Patients on Hemodialysis: Tokai Dialysis Cohort Study (KIDNEY WEEK 2025) - "Patients with higher serum 25(OH)D levels were more likely to be female; were less likely to have diabetes, a history of cerebral infarction, or peripheral arterial disease; had higher serum albumin and creatinine levels; and were more frequently prescribed lanthanum carbonate and active vitamin D. There was no association between 25(OH)D levels and serum calcium, phosphorus, or intact parathyroid hormone (PTH) levels...These findings suggest that vitamin D deficiency has at most a limited impact on bone metabolism in patients undergoing hemodialysis. Further studies are needed to clarify the role of 25(OH)D in bone metabolism in kidney failure."

Clinical • Cardiovascular • Chronic Kidney Disease • CNS Disorders • Diabetes • Diabetic Nephropathy • Metabolic Disorders • Musculoskeletal Diseases • Nephrology • Orthopedics • Peripheral Arterial Disease • Renal Disease

Oxylanthanum Carbonate Achieves Serum Phosphate Control with Significantly Lower Pill Burden in Patients with Hyperphosphatemia on Dialysis (KIDNEY WEEK 2025) - "Pretrial PB included sevelamer carbonate, calcium acetate, ferric citrate, and sucroferric oxyhydroxide. Combined with previously presented safety data, these findings suggest that OLC is safe, effective, and well-tolerated. Its small, easy-to-swallow formulation may be a welcome choice for pts with HP."

Clinical • Chronic Kidney Disease • Metabolic Disorders • Nephrology • Renal Disease

Comparative Phosphate-Lowering Effects of Tenapanor in Combination with Different Phosphate Binders in Patients on Hemodialysis: A Prospective Pilot Study (KIDNEY WEEK 2025) - "Methods In this prospective study, 55 HD patients were stratified into five groups based on their baseline phosphate binder (PB) use: PB-naïve, calcium-based binders, iron-based binders (ferric citrate), lanthanum carbonate, and polymer-based binders. Although the exact mechanism remains unclear, it is hypothesized that iron-based binders such as ferric citrate may alter intestinal pH—potentially affecting the local action of tenapanor. These preliminary results highlight the importance of binder selection in maximizing tenapanor efficacy and warrant further mechanistic and clinical studies."

Clinical • Combination therapy • Cardiovascular • Metabolic Disorders • Nephrology • Renal Disease

Lanthanum Carbonate-Induced Gastritis Presenting with Melena in a Patient with End Stage Renal Disease (ACG 2025) - "A trial of omeprazole twice daily provides no relief. In patients with unexplained upper GI symptoms or melena on lanthanum therapy, it is important to consider biopsy even in the setting of normal endoscopy. Discontinuation of lanthanum carbonate and switching to alternative binders often leads to symptom resolution."

Clinical • Anemia • Chronic Kidney Disease • Endocrine Disorders • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Inflammation • Metabolic Disorders • Nephrology • Renal Disease • Secondary Hyperparathyroidism

Crystalline Colitis: A Rare Adverse Effect of Sevelamer Therapy (ACG 2025) - "Home medications included sevelamer carbonate dosed at 2400mg three times daily...Given the presence of sevelamer crystals, the medication was discontinued and replaced with lanthanum carbonate. Sevelamer-induced colitis should be considered in dialysis patients presenting with unexplained colitis, especially when infectious and ischemic causes have been ruled out...Delayed recognition may lead to unnecessary treatments, prolonged symptoms, and increased morbidity. Early identification and discontinuation of sevelamer, with substitution by an alternative phosphate binder, are essential for symptom resolution and prevention of further gastrointestinal injury.Figure: Images A, B, C: Diffuse, severe inflammation found in the proximal transverse colon during colonoscopy."

Adverse events • Atrial Fibrillation • Cardiovascular • Chronic Kidney Disease • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Nephrology • Renal Disease

Whitish Deposits in the Stomach and Duodenum. (PubMed, United European Gastroenterol J) - No abstract available

Journal

Lanthanum carbonate lowers serum phosphorus without altering body phosphorus burden in maintenance peritoneal dialysis patients: a randomized crossover trial. (PubMed, Am J Clin Nutr) - P=N/A | "La2(CO3)3 treatment lowered serum phosphorus concentration but did not change body phosphorus content. This trial was registered at clinicaltrials.gov as NCT01581996."

Journal • Chronic Kidney Disease • Nephrology • Renal Disease

Colorimetric Detection of Platinum (IV) Using 4-MethylSulfonylaniline-Modified Gold Nanoparticles in Lanthanum Carbonate API. (PubMed, Sensors (Basel)) - "Under optimal conditions, LOD and LOQ values of 10.00 × 10-3 μM and 3.03 × 10-2 μM, respectively, were observed. This method has been successfully applied to the determination of platinum (IV) in lanthanum carbonate API."

Journal

Hierarchically cactus-like nickel sulfide-lanthanum carbonate hydroxide composite for urea-assisted water splitting. (PubMed, J Chem Phys) - "Assembling NiSx-LaCH/NF into urea electrolysis system can reduce the cell voltage by 0.22 V compared to water electrolysis. This indicates that using UOR instead of OER could achieve energy-saving hydrogen production and has promising prospects in treating urea-rich wastewater."

Journal

A Phase 2 Clinical Trial of Oxylanthanum Carbonate in Patients Receiving Maintenance Hemodialysis with Hyperphosphatemia. (PubMed, Clin J Am Soc Nephrol) - "In this open-label Phase 2 trial, OLC was well tolerated and enabled sP control in >90% of patients with a low pill burden (two-thirds of patients receiving three or fewer tablets/day)."

Journal • P2 data • Metabolic Disorders • Nephrology • Renal Disease

A Case of Intestinal Granular Calcifications Associated With Phosphate Binder Use in a Patient on Hemodialysis. (PubMed, Clin Case Rep) - "An experienced physician correctly identified a high-intensity intestinal X-ray from Lanthanum Carbonate, preventing unnecessary tests and enabling proper treatment. Awareness of this is vital in managing renal failure patients."

Journal • Metabolic Disorders • Nephrology • Renal Disease

Efficacy of tenapanor in managing hyperphosphatemia and constipation in hemodialysis patients: A randomized controlled trial. (PubMed, PLoS One) - "Tenapanor improves stool consistency, reduces laxative use, and provides effective phosphorus control in hemodialysis patients and represents a promising alternative to conventional phosphate binders."

Clinical • Journal • Constipation • Gastroenterology • Gastrointestinal Disorder • Metabolic Disorders • Nephrology • Renal Disease

Lanthanum carbonate does not reduce urinary oxalate excretion in hyperoxaluric kidney stone formers (ERA 2025) - "Short-term treatment with LaCa at doses up to 1500 mg did not reduce urinary oxalate excretion in kidney stone formers with idiopathic hyperoxaluria. Urinary phosphate excretion decreased slightly without effect on serum phosphate levels. LaCa in its current formulation is not a good treatment for the reduction of urinary oxalate excretion in kidney stone formers with idiopathic hyperoxaluria."

Nephrology • Renal Calculi

Tenapanor administration combined with phosphate binders provides synergistic phosphate lowering effect (ERA 2025) - "Six types of P binders had been used in Group Ad (sevelamer hydrochloride, bixalomer, calcium carbonate, ferric citrate, sucroferric oxyhydroxide hydrate and lanthanum carbonate hydrate). Oral administration of tenapanor significantly reduced P adsorption and improved serum P level in patients undergoing HD either when it was administrated alone or adding on P binders. This P absorption reduction effect of tenapanor was greatly enhanced when it was added on P binders. The mechanism of this synergistic effect would be an important research question."

Metabolic Disorders • Nephrology • Renal Disease

Gastric Mucosal Calcinosis Case Study: A Diagnosis to Consider in People with Kidney Failure and Gastrointestinal Symptoms? (UKKW 2025) - "Relevant medication history: alfacalcidol (250-500ng daily), cholecalciferol (60,000units fortnightly), cinacalcet (changed to Etelcalcitide 2024), lanthanum carbonate (stopped in 2023), sevelamer carbonate (2023-present). There is no prevalence, or outcome, data reported for gastric mucosal calcinosis; it may be underdiagnosed. The calciphylaxis rare disease registry, and UK renal registry, may offer an opportunity to undertake research to better understand the disease process, risk factors and prevalence."

Case study • Clinical • Anorexia • Calciphylaxis • Chronic Kidney Disease • Endocrine Disorders • Gastroenterology • Glomerulonephritis • IgA Nephropathy • Metabolic Disorders • Nephrology • Oncology • Pain • Rare Diseases • Renal Disease • Secondary Hyperparathyroidism

Crystal-Storing Histiocytosis of the Duodenum in a Patient With IgG-Lambda Multiple Myeloma. (PubMed, Int J Surg Pathol) - "We report a 70-year-old man with a history of IgG-lambda multiple myeloma, systemic amyloidosis, and end-stage renal disease managed with peritoneal dialysis and long-term lanthanum carbonate therapy for hyperphosphatemia, who presented with gastrointestinal bleeding...Differential diagnoses, including Whipple disease, mycobacterial infections, lanthanum deposition, amyloidosis, and xanthoma, were excluded based on histological findings and clinical history. This report highlights the importance of recognizing crystal-storing histiocytosis in uncommon sites such as the duodenum, especially in the context of plasma cell dyscrasias."

Journal • Amyloidosis • Chronic Kidney Disease • Gastroenterology • Gastrointestinal Disorder • Hematological Malignancies • Infectious Disease • Metabolic Disorders • Multiple Myeloma • Nephrology • Oncology • Renal Disease • CD68

Momentum toward patient outcome trials in chronic kidney disease-mineral bone disorder. (PubMed, Curr Opin Nephrol Hypertens) - "More intensive treatment of CKD-MBD remains a promising approach to improve clinical outcomes in patients with kidney failure and should prompt ongoing efforts to obtain needed trials."

Journal • Cardiovascular • Chronic Kidney Disease • Endocrine Disorders • Metabolic Disorders • Nephrology • Orthopedics • Renal Disease

Direct Nano-Imaging Reveals the Underestimated Role of Lanthanum Phosphate Formation in Phosphorus Sequestration by Lanthanum Carbonate. (PubMed, Environ Sci Technol) - "A dissolution-nucleation-growth mechanism was then proposed for the interfacial formation of LaPO4. This study revises the mechanistic framework for phosphorus removal and highlights the crucial role of LaPO4 formation in maximizing the utilization efficiency of lanthanum active sites for enhanced phosphate sequestration by La-based materials."

Journal

Comparison of the efficacy of sucroferric oxyhydroxide and lanthanum carbonate in the hyperphosphatemia of maintainable Hemodialysis. (PubMed, BMC Pharmacol Toxicol) - "SFOH was superior to LC in lowering patients' blood phosphorus and iPTH levels in patients with maintenance hemodialysis hyperphosphatemia combined with secondary hyperparathyroidism."

Journal • Endocrine Disorders • Metabolic Disorders • Nephrology • Renal Disease • Secondary Hyperparathyroidism

Radiopaque Medication Mimicking Esophageal Foreign Body: A Case of Lanthanum Carbonate Misidentification. (PubMed, Am J Gastroenterol) - No abstract available

Journal

Patient-Reported Outcomes in a Pivotal Clinical Study of Hyperphosphatemia: Oxylanthanum Carbonate Reduces Pill Burden by Half and Improves Adherence (NKF-SCM 2025) - "A high proportion of patients preferred OLC over their pretrial PBs. These PROs, along with previously presented safety data, suggest that OLC is safe, effective, well-tolerated, is formulated in a small, easy-to-swallow pill, and may be a welcome choice for patients with HP."

Adherence • Clinical • Patient reported outcomes • Chronic Kidney Disease • Gastrointestinal Disorder • Metabolic Disorders • Nephrology • Renal Disease

Pill Burden and Large Tablet Size Are Top Barriers to Phosphate Binder Adherence in Dialysis Patients (NKF-SCM 2025) - "2 Oxylanthanum carbonate (OLC) is a lanthanum based PB with a low pill number and small tablet size...These data suggest fewer pill numbers and smaller pill size may improve adherence to PB. OLC, a novel PB with the characteristics of reduced pill numbers and pill size, may be a promising solution to address pts' challenges in adherence, thereby improving quality of life and clinical outcomes."

Adherence • Clinical • Nephrology • Orthopedics • Renal Disease